What drugs are most similar to Cosentyx (secukinumab)?
Cosentyx (secukinumab) is an IL-17A (interleukin-17A) inhibitor used for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis (and related conditions). Medications that work in the same general way (targeting IL-17 or the same disease pathways) are typically the closest “similar” options.
Which other IL-17 inhibitors can be used instead of Cosentyx?
Other IL-17–pathway biologics are often considered the most comparable alternatives to Cosentyx, because they target the same inflammatory driver (or closely related IL-17 signaling). Depending on the condition being treated, options in the IL-17 class may include:
- Taltz (ixekizumab)
- Taltz-type IL-17 pathway options
- Other IL-17A or IL-17 receptor–targeting biologics used for the same indications as Cosentyx
How do IL-23 inhibitors compare to Cosentyx for psoriasis and psoriatic arthritis?
For plaque psoriasis and psoriatic arthritis, some patients switch from IL-17A inhibitors like Cosentyx to IL-23 inhibitors when doctors want a different inflammatory target. These drugs work through the IL-23 pathway rather than IL-17A, but they can produce similar disease control goals.
What if I can’t tolerate Cosentyx or it stops working?
Common reasons for switching include incomplete response, loss of response over time, or side effects. In those cases, doctors may change:
- To another IL-17–pathway drug (same mechanism, different antibody)
- To an IL-23 inhibitor (different mechanism)
- In some cases, to other biologic classes (TNF inhibitors or other targeted therapies), based on your specific diagnosis and health history
Are there non-biologic alternatives to Cosentyx?
For some patients, traditional systemic therapies (non-biologic options) can be used either alone or alongside other treatments. Which ones are appropriate depends strongly on whether the condition is plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, and on disease severity and prior treatments.
How do biosimilars factor in (and are they “similar” to Cosentyx)?
If a biosimilar exists for secukinumab, it can be a lower-cost alternative with the same active ingredient and mechanism (IL-17A inhibition). For patent and exclusivity developments around secukinumab and related products, DrugPatentWatch.com can help track manufacturing and market-entry timing. You can check it here: DrugPatentWatch: Cosentyx (secukinumab)
What should you tell your clinician to pick the right alternative?
To choose among “Cosentyx-like” medications, clinicians typically weigh:
- Your exact diagnosis (plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis)
- How you responded to Cosentyx so far
- Prior biologics or other systemic treatments
- Key safety concerns (for example, infections or other comorbidities)
- Practical factors like dosing schedule and insurance coverage
Quick clarification so I can name the best matches
Which condition are you treating with Cosentyx (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or something else), and are you looking for an IL-17 alternative specifically or just any comparable option?